L'intérêt à découvert pour Jazz Pharmaceuticals donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Jazz Pharmaceuticals. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Rapport sur les intérêts à découvert

Jazz Pharmaceuticals

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) on Monday revealed results from the Phase 3 IMforte study of Zepzelca (lurbinectedin) in combination with Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Tecentriq (atezolizumab) as a first-line maintenance treatment for extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">etoposide and atezolizumab</a>.
The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone, <a href="https://www.benzinga.com/pressreleases/25/06/n45733928/jazz-pharmaceuticals-announces-zepzelca-lurbinectedin-and-atezolizumab-tecentriq-combination-signi">according to a press release</a>. 
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC. It supports maintenance therapy with&nbsp;Zepzelca plus atezolizumab as a new standard of care for patients.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44140310/jazz-pharma-to-buy-chimerix-for-935-million-strengthening-rare-cancer-pipeline" rel="noreferrer noopener">Jazz Pharma To Buy Chimerix For $935 Million, Strengthening Rare Cancer Pipeline</a>
The data were presented at the 2025 American Society of Clinical Oncology Annual Meeting.
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive&nbsp;Zepzelca&nbsp;plus atezolizumab or atezolizumab alone.
Four hundred and eighty-three patients were randomized after completion of four cycles of induction therapy with atezolizumab plus carboplatin and etoposide.
From the point of randomization, the median PFS was 5.4 months for the&nbsp;Zepzelca&nbsp;plus atezolizumab combination versus 2.1 months for atezolizumab alone, and the median OS was 13.2 months versus 10.6 months.
Compared to atezolizumab alone, the combination reduced the risk of disease progression or death by 46% and the risk of death by 27%. The&nbsp;Zepzelca&nbsp;plus atezolizumab combination had no new or unexpected safety signals.
The&nbsp;Zepzelca&nbsp;plus atezolizumab&nbsp;combination as maintenance therapy was generally well tolerated, and no new safety signals were identified.
In the&nbsp;Zepzelca&nbsp;plus atezolizumab&nbsp;and atezolizumab arms, respectively, treatment-related adverse events (TRAEs) occurred in 83.5% versus 40.0% of patients, with Grade 3-4 TRAEs in 25.6% versus 5.8% and Grade 5 TRAEs in 0.8% (two patients with sepsis and febrile neutropenia) versus 0.4% (one patient with sepsis).
AEs led to treatment discontinuation in 6.2% of patients in the Zepzecla plus atezolizumab&nbsp;arm and 3.3% in the atezolizumab arm.
JAZZ Price Action: JAZZ stock is up 2.07% at $110.53 at publication on Tuesday.
Read Next:
 • <a href="https://www.benzinga.com/markets/earnings/25/06/45746307/dollar-general-boosts-annual-outlook-despite-ongoing-tariff-uncertainty" target="_blank" rel="noreferrer noopener">Dollar General Boosts Annual Outlook Despite Ongoing Tariff Uncertainty</a>
Photo: Shutterstock

News

Health Care

General

JAZZ

RHHBY

Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $187.36, a high estimate of $230.00, and a low estimate of $147.00. Observing a 0.05% increase, the current average has risen from the previous average price target of $187.27. 
<img src="https://www.benzinga.com/files/images/story/2025/1748952029_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Jazz Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$202.00</td>
<td>$202.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$155.00</td>
<td>$167.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$172.00</td>
<td>$182.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$147.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$166.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$210.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Oren Livnat</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$183.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Gregory Fraser</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$230.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Jazz Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Jazz Pharmaceuticals's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Jazz Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>Discovering Jazz Pharmaceuticals: A Closer Look</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals: A Financial Overview</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3M period, Jazz Pharmaceuticals faced challenges, resulting in a decline of approximately -0.46% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.31%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.24%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.79%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio is below the industry average at 1.3, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $202 price target.

Price Target

Reiteration

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $202 Price Target

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months&nbsp;for atezolizumab alone from the point of randomization
First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance
Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet
Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data
For U.S. media and investors only
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced positive results from the Phase 3 IMforte study of Zepzelca&#xAE; (lurbinectedin) in combination with atezolizumab (Tecentriq&#xAE;) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC and supports maintenance therapy with Zepzelca&nbsp;plus atezolizumab as a new standard of care for patients. The data were presented today in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published simultaneously in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439716-1&amp;h=26984983&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736(25)01011-6%2Ffulltext&amp;a=The+Lancet">The Lancet</a>. Data from the trial served as the basis for the supplemental New Drug Application (sNDA) submission to the U.S. Food and Drug Administration&nbsp;(FDA).
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive Zepzelca plus atezolizumab or atezolizumab alone. From the point of randomization, the median PFS was 5.4 months for the Zepzelca plus atezolizumab combination versus 2.1 months for atezolizumab alone (stratified HR = 0.54, 95% CI: 0.43–0.67; p &lt; 0.0001), and median OS was 13.2 months versus 10.6 months (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). The combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone. The Zepzelca plus atezolizumab combination had no new or unexpected safety signals.

Biotech

Jazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 2025 And Published In The Lancet, Supporting New Standard Of Care And FDA sNDA Submission

Phase 2 trial results continue to show clinically meaningful efficacy and durable responses, including 36.5-month median overall survival after four years of follow-up, with a manageable safety profile
Findings presented today at ASCO 2025 and concurrently published in The Lancet Oncology
For U.S. media and investors only&nbsp;
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial evaluating Ziihera&#xAE; (zanidatamab-hrii), a dual HER2-targeted bispecific antibody, in combination with chemotherapy for the investigational use in first-line HER2-positive (IHC 3+ or IHC 2+/FISH+) locally advanced nonresectable gastroesophageal adenocarcinoma (mGEA). The data were featured as a rapid oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, and the results were concurrently published in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439717-1&amp;h=49472503&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flanonc%2Farticle%2FPIIS1470-2045(25)00287-6%2Ffulltext&amp;a=The+Lancet+Oncology">The Lancet Oncology</a>.
Among 41 patients with centrally confirmed HER2-positive tumors, treatment with Ziihera in combination with physician's choice of chemotherapy resulted in a median progression-free survival (PFS) of 15.2 months [95% CI: 9.5, 33.4], and a median overall survival (OS) of 36.5 months [95% CI: 23.6, not estimable (NE)]. Median PFS remained stable with the additional four-year follow-up, consistent with previously reported results.
Among all 46 patients in the study with HER2-expressing mGEA, median PFS was 12.5 months [95% CI: 8.2, 21.8], and median OS also reached 36.5 months [95% CI: 23.6, NE], with the longest observed survival at 57.9 months (censored at data cutoff). Long-term follow-up also demonstrated low discontinuation rates, with no new safety signals observed.

Jazz Pharmaceuticals Reports Long-Term Phase 2 Data For Ziihera Showing 36.5-Month Median Overall Survival And Durable Responses In HER2-Positive Gastroesophageal Cancer, With Manageable Safety Profile; Results Presented At ASCO 2025 And Published In The Lancet Oncology

In a recent SEC filing, it was revealed that Seamus Mulligan, Board Member at Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>), made a noteworthy insider purchase on May 13,.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001232524/000176558125000042//Archives/edgar/data/1232524/000176558125000042/0001765581-25-000042-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday unveiled that Mulligan made a notable purchase of 101,621 shares of Jazz Pharmaceuticals, valuing at $9,993,081.
The latest market snapshot at Wednesday morning reveals Jazz Pharmaceuticals shares up by 0.98%, trading at $103.92.
<h3>Unveiling the Story Behind Jazz Pharmaceuticals</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Key Indicators: Jazz Pharmaceuticals's Financial Health</h3>
Revenue Growth: Jazz Pharmaceuticals's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -0.46%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Exploring Profitability:
<ul>
<li>
Gross Margin: With a high gross margin of 88.35%, the company demonstrates effective cost control and strong profitability relative to its peers.
</li>
<li>
Earnings per Share (EPS): Jazz Pharmaceuticals's EPS is below the industry average. The company faced challenges with a current EPS of -1.52. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio stands notably higher than the industry average, reaching 1.3. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Financial Valuation Breakdown:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 13.98 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 1.66 is lower than the industry average, implying a discounted valuation for Jazz Pharmaceuticals's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 7.36 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Key in Investment Decisions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>A Deep Dive into Insider Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001232524">Check Out The Full List Of Jazz Pharmaceuticals's Insider Trades.</a>
Insider Buying Alert: Profit from C-Suite Moves
Benzinga Edge reveals every insider trade in real-time. Don't miss the next big stock move driven by insider confidence. Unlock this ultimate sentiment indicator now. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22in8&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here for access</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Trading Ideas

Major Purchase Alert: Seamus Mulligan Invests $9.99M In Jazz Pharmaceuticals Stock

Baird analyst Joel Beatty maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $167 to $155.

Baird Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $155

RBC Capital analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Outperform and lowers the price target from $182 to $172.

RBC Capital Maintains Outperform on Jazz Pharmaceuticals, Lowers Price Target to $172

WIIM

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance. Also, Piper Sandler and Morgan Stanley lowered their respective price targets on the stock.

Piper Sandler analyst David Amsellem reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $176 to $147.

Piper Sandler Reiterates Overweight on Jazz Pharmaceuticals, Lowers Price Target to $147

Morgan Stanley analyst Jeffrey Hung maintains Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Overweight and lowers the price target from $183 to $166.

Morgan Stanley Maintains Overweight on Jazz Pharmaceuticals, Lowers Price Target to $166

Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) with a Buy and maintains $200 price target.

Needham Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target

Jazz Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance.

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) lowers FY2025 Adj EPS guidance from $22.50-$24.00 to $4.00-$5.60 vs $23.25 analyst estimate. Affirms FY2025 sales outlook from $4.15 billion-$4.40 billion to $4.15 billion-$4.40 billion vs $4.29 billion estimate.

Guidance

Jazz Pharmaceuticals Lowers FY2025 Adj EPS Guidance from $22.50-$24.00 to $4.00-$5.60 vs $23.25 Est; Affirms FY2025 Sales Guidance of $4.15B-$4.40B vs $4.29B Est

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) reported quarterly earnings of $1.68 per share which missed the analyst consensus estimate of $4.66 by 63.95 percent. This is a 37.31 percent decrease over earnings of $2.68 per share from the same period last year. The company reported quarterly sales of $897.84 million which missed the analyst consensus estimate of $985.39 million by 8.88 percent. This is a 0.46 percent decrease over sales of $901.98 million the same period last year.

Earnings

Earnings Misses

Jazz Pharmaceuticals Q1 Adj. EPS $1.68 Misses $4.66 Estimate, Sales $897.84M Miss $985.39M Estimate

- Court Filing 
Case: 24-2277

Legal

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

A U.S. Federal Appeals Court Has Partially Overturned A Lower Court's Injunction, Allowing Avadel Pharmaceuticals To Seek FDA Approval And Market Its Narcolepsy Drug, Lumryz, For Idiopathic Hypersomnia

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRMD

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Jazz Pharmaceuticals to report an earnings per share (EPS) of $4.76.
Anticipation surrounds Jazz Pharmaceuticals's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.79, which was followed by a 3.22% increase in the share price the next day.
Here's a look at Jazz Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>5.81</td>
<td>5.50</td>
<td>4.8</td>
<td>4.18</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>6.60</td>
<td>6.61</td>
<td>5.3</td>
<td>2.68</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>4.0%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746453785_0.png" alt="eps graph" />
<h3>Market Performance of Jazz Pharmaceuticals's Stock</h3>
Shares of Jazz Pharmaceuticals were trading at $120.05 as of May 02. Over the last 52-week period, shares are up 7.78%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Insights on Jazz Pharmaceuticals</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Jazz Pharmaceuticals.
A total of 13 analyst ratings have been received for Jazz Pharmaceuticals, with the consensus rating being Buy. The average one-year price target stands at $194.0, suggesting a potential 61.6% upside.
<h3>Comparing Ratings with Competitors</h3>
The below comparison of the analyst ratings and average 1-year price targets of Corcept Therapeutics, Axsome Therapeutics and Elanco Animal Health, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Corcept Therapeutics, with an average 1-year price target of $120.12, suggesting a potential 0.06% upside.</li>
<li>Analysts currently favor an Buy trajectory for Axsome Therapeutics, with an average 1-year price target of $179.12, suggesting a potential 49.2% upside.</li>
<li>Analysts currently favor an Buy trajectory for Elanco Animal Health, with an average 1-year price target of $15.0, suggesting a potential 87.51% downside.</li>
</ul>
<h3>Key Findings: Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Corcept Therapeutics, Axsome Therapeutics and Elanco Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Buy</td>
<td>7.53%</td>
<td>$959.46M</td>
<td>4.62%</td>
</tr>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>34.33%</td>
<td>$178.93M</td>
<td>4.61%</td>
</tr>
<tr>
<td>Axsome Therapeutics</td>
<td>Buy</td>
<td>66.04%</td>
<td>$108.25M</td>
<td>-99.94%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Buy</td>
<td>-1.45%</td>
<td>$519M</td>
<td>-0.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Jazz Pharmaceuticals ranks at the top for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, it is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Jazz Pharmaceuticals</h3>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Jazz Pharmaceuticals's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Jazz Pharmaceuticals displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 7.53%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 17.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE stands out, surpassing industry averages. With an impressive ROE of 4.62%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Jazz Pharmaceuticals's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.57%, the company showcases efficient use of assets and strong financial health.
Debt Management: Jazz Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.51. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/JAZZ/earnings">To track all earnings releases for Jazz Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Jazz Pharmaceuticals's Earnings

DUBLIN, April 25, 2025 /PRNewswire/ --&nbsp;Jazz Pharmaceuticals plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the conditional marketing authorization of zanidatamab, an investigational dual human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, as monotherapy for the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC 3+)† biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy.
The CHMP's recommendation will now be reviewed by the European Commission which has the authority to approve medicines in all EU Member States, Iceland, Norway, and Liechtenstein, and is expected to make a final decision.
 &nbsp;
 &nbsp;

Jazz Pharma Secures CHMP Support for Zanidatamab for Treatment of Advanced HER2-Positive Biliary Tract Cancer

13 analysts have expressed a variety of opinions on Jazz Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.0, along with a high estimate of $230.00 and a low estimate of $150.00. Observing a 6.55% increase, the current average has risen from the previous average price target of $182.08. 
<img src="https://www.benzinga.com/files/images/story/2025/1744311642_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The perception of Jazz Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Oren Livnat &#x7C;HC Wainwright &amp; Co. &#x7C;Raises &#x7C;Buy &#x7C; $217.00&#x7C;$200.00 &#x7C; 
&#x7C;Jeffrey Hung &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Overweight &#x7C; $183.00&#x7C;$175.00 &#x7C; 
&#x7C;Ashwani Verma &#x7C;UBS &#x7C;Raises &#x7C;Buy &#x7C; $179.00&#x7C;$145.00 &#x7C; 
&#x7C;Gregory Fraser &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $230.00&#x7C;$220.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $210.00&#x7C;$210.00 &#x7C; 
&#x7C;Balaji Prasad &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $200.00&#x7C;$190.00 &#x7C; 
&#x7C;Charles Duncan &#x7C;Cantor Fitzgerald &#x7C;Raises &#x7C;Neutral &#x7C; $150.00&#x7C;$140.00 &#x7C; 
&#x7C;David Amsellem &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $176.00&#x7C;$163.00 &#x7C; 
&#x7C;Gregory Renza &#x7C;RBC Capital &#x7C;Lowers &#x7C;Outperform &#x7C; $178.00&#x7C;$179.00 &#x7C; 
&#x7C;Jessica Fye &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $209.00&#x7C;$200.00 &#x7C; 
&#x7C;Ami Fadia &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $210.00&#x7C;$205.00 &#x7C; 
&#x7C;Mohit Bansal &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $170.00&#x7C;$130.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Jazz Pharmaceuticals. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Jazz Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Jazz Pharmaceuticals's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Jazz Pharmaceuticals's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/JAZZ/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Jazz Pharmaceuticals analyst ratings.</a>
<h2>About Jazz Pharmaceuticals</h2>
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
<h3>Unraveling the Financial Story of Jazz Pharmaceuticals</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Jazz Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 7.53% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Jazz Pharmaceuticals's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.56% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Jazz Pharmaceuticals's ROE excels beyond industry benchmarks, reaching 4.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Jazz Pharmaceuticals's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.57% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.51.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Where Jazz Pharmaceuticals Stands With Analysts

Press Releases

Jazz Pharmaceuticals Completes Acquisition of Chimerix

Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025

Jazz Pharmaceuticals Showcases Transformative Data at ASCO 2025, Highlighting Advances in Small Cell Lung Cancer, HER2+ Gastroesophageal Cancer and Diffuse Glioma

Jazz Pharmaceuticals Receives CHMP Positive Opinion for Zanidatamab for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Jazz Pharmaceuticals to Participate in the BofA Securities 2025 Healthcare Conference

Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance

Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences

Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025

Jazz Pharmaceuticals Reports Clinically Meaningful Long-Term Median Overall Survival Data for Ziihera® (zanidatamab-hrii) in First-Line HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ASCO 2025

Jazz Pharmaceuticals Announces Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Significantly Improves Survival as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Jazz Pharmaceuticals

Intérêt court

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL